Nowadays, medical technology has become more advanced, making biotechnology Medicine, which is a combination of technology and knowledge of biology. has come to play a greater role both in the production of medicines that are more precisely the point Vaccines against new diseases such as COVID-19, detection of various diseases Genetic from genes or the introduction of Antibody used in the production of medicines. Today, there are many companies investing in research. To invent drugs or vaccines, including methods for treating rare diseases
Get to know Medical Biotechnology Company
- Regeneron – a company that manufactures a wide range of medicines.
Regeneron Company is an American company. Which is considered a large pharmaceutical company (market value $65.7 billion, compared to PTT company market value $25.8 billion as of July 14, 2022) produces a wide range of drugs. The company’s main drug, Eylea, is an anti-VEGF drug, an injectable drug for the treatment of eye diseases such as wet macular degeneration (Wet AMD), which often occurs in older adults. which will make your vision worse or can lose sight at all If not urgent treatment or diabetic retinal detachment (DME) or diabetic retinopathy (DR) that will cause abnormal vision in patients or may have dimmed eyes Which in the treatment of these diseases will be done by injecting drugs into the white of the eye. which is considered a cure at the root cause and see results quickly Eyelea has been used in over 20 million ophthalmic treatments since 2011, the year Eyelea was approved by the FDA.
The new drugs that passed the FDA in 2017 include Dupixent, a drug for inflammatory skin diseases, and Libtayo, a drug for skin cancer. Regeneron recently collaborated with Roche to develop an antibody cocktail for COVID-19 patients. The drug will enter and weaken the virus. And it is considered a drug used to treat COVID-19 directly as well.
In addition to various drugs foregoing Currently, the company is actively researching more than 30 new drugs, and many of them are in Phase 3, which is the final phase before filing for FDA approval to allow for distribution and use.
- Argenx – a pharmaceutical research and production company.
Argenx is a company Biotechnology From the Netherlands that research and develop medicines for diseases such as muscle weakness. immune thrombocytopenia Blister disease caused by immune deficiency The company is still in a period of high investment costs in technology tools. and will cooperate with partner companies to develop various drugs
The company currently distributes VYVGART, a drug for patients with myasthenia gravis, a disease caused by an immune system disorder. As a result, the function of neurotransmitters in the space between nerves and muscles is impaired. This causes the patient to have weakness in many parts of the body, for example, if the eye muscles are weak, the eyelids will fall. or blurred vision Weakness in the facial muscles and digestive system can lead to slurred speech, difficulty chewing and swallowing. and if the muscles of the limbs are weak will be difficult to move which will not be able to reach the arm Can’t go up and down stairs
In addition, the company is in the process of developing drugs for muscle weakness. and medication for thrombocytopenia, which is already in Phase 3, which if approved It will be able to make the company earn more.
The image shows the drug that is currently being developed by the company.
from the development of technology causing new medical innovations which led to the invention of various rare medicines including more effective vaccines We believe that in the future, the biotechnology industry will be one of the industries that has developed by leaps and bounds.
company Biotechnology These are considered some in the industry. Healthcare believes that the business group will have limited impact During the uncertainty of the world economy But the need to cure disease is still necessary. While in the near future new types of drugs which is still under review by the FDA if it can be approved successfully It will help to grow the company’s business by leaps and bounds.
ที่มา: Argenx, Regeneron, Chula Communication Center, Medparkhospital, Phyathai Hospital, Bumrungrad International Hospital, MedPark Hospital
Information, articles, analysis and forecasts and all opinions contained in this report are made on the basis of the best sources of information obtained and considered reliable, but the accuracy, completeness and authenticity of such information cannot be guaranteed. The opinions expressed in this report are based on reasonable and careful consideration. and are subject to change without notice. All articles, analyzes and expectations are displayed. Any use contained in this report is used at the user’s own risk and at the user’s sole discretion.
Contact for more details at TISCO Asset Management Co., Ltd. or TISCO Contact Center Tel. 0 2633 6000 press 4, 0 2080 6000 press 4 and www.tiscoasset.com or TISCO My Funds application.
